10-K: PMGC posts small revenue, big loss, eyes IND in 2026

PMGC Holdings reported $0.59M in first-year operating revenue and a $7.75M net loss, executed dilutive financings backed by pledged subsidiaries, and plans to advance lead biotech asset EL-22 toward a U.S. IND in 2026.

Summary

• Business model: diversified holding company with four wholly owned subsidiaries—Northstrive Biosciences (biotech), PMGC Capital (investments), Pacific Sun Packaging (IT hardware packaging), and AGA Precision Systems (precision CNC machining).
• Portfolio reshape: divested Elevai Skincare on January 16, 2025; acquired Pacific Sun Packaging (July 7, 2025), AGA Precision Systems (July 18, 2025), and Indarg Engineering assets into AGA (October 26, 2025).
• Revenue: $590,084 in 2025 (2024: $0); gross profit $185,314 (31.4% GM). Segment revenue: Pacific Sun $374,874 (GM 29.1%; ~49.2% normalized excluding PPA step-up), AGA $215,210 (GM 35.4%).
• Losses: net loss from continuing operations $(7,780,740); total net loss $(7,747,813) vs $(6,245,737) in 2024; accumulated deficit $21,017,440.
• Operating expenses: $7,067,262, including consulting $1,769,505, office/admin $2,238,660, professional fees $1,423,021, repairs/maintenance $717,654 as AGA/Indarg were optimized.
• Cash and liquidity: cash $5,402,333; current assets $6,871,255; current liabilities $3,942,296; working capital $2,928,959; operating cash outflow ~$5.8M; going-concern uncertainty disclosed.
• Financing: Raised ~$1.67M net via ATM, ~$1.25M net via registered direct (Mar 2025), ~$3.21M via warrant exercises; entered a $5.0M principal secured pre-paid equity purchase (Sept 26, 2025), net ~$3.99M, convertible at 88% of VWAP with a floor; pledged 100% equity and substantially all assets of AGA and Pacific Sun as collateral.
• Other P&L items: $500,000 impairment on prepaid expense (non-performance under a manufacturing contract); net investment losses (realized $113,917; unrealized $216,043); derivative liability fair-value gain $214,167.
• Capital structure: multiple reverse stock splits (1:200, 1:7, 1:3.5 in 2024–2025; 1:4 and 1:6 in 2026); shares outstanding 1,159,112 as of March 30, 2026.
• Biotech pipeline: EL-22 (engineered probiotic) completed Phase 1 safety in South Korea; pre-IND meeting request submitted Feb 18, 2025; Company targets IND submission in 2026. EL-32 in preclinical stage.
• Governance and related parties: CEO also serves as CFO; significant consulting and secondment fees to entities controlled by CEO and Chairman; 6,372,874 Series B Preferred issued to CEO/Chairman-controlled entities with concentrated voting rights.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as negative: limited revenue against high burn, going-concern uncertainty, dilutive financing with pledged collateral, and governance risks outweigh early-stage pipeline potential.

Positives

• First operating revenue posted: $590,084 in 2025 from newly acquired subsidiaries.
• Healthy product-level margins: AGA 35.4% GM; Pacific Sun normalized GM ~49.2% (post-PPA adjustment it reported 29.1%).
• Cash balance of $5.40M and positive financing inflows ($10.12M) extended runway into 2026.
• Biotech progress: EL-22 completed Phase 1 safety and a pre-IND meeting request was filed with FDA on February 18, 2025.
• Portfolio diversification accomplished with two platform acquisitions (packaging and precision machining) and an asset tuck-in (Indarg).
• Material weakness in internal control reported in 2024 was remediated by year-end 2025.

Negatives

• Net loss widened to $(7.75)M with operating cash burn of roughly $(5.8)M and a going‑concern warning.
• Working capital fell to $2.93M while current liabilities rose to $3.94M, stressing near‑term liquidity.
• Highly dilutive financing: secured pre‑paid equity line convertible at a discount (88% of VWAP) with a floor price, plus multiple reverse stock splits.
• Collateral risk: 100% equity and substantially all assets of AGA and Pacific Sun pledged; default could result in loss of operating businesses.
• Impairment: $500,000 prepaid written off due to counterparty non‑performance; net realized/unrealized investment losses totaled ~$330,000.
• Heavy corporate overhead ($7.07M opex) relative to $0.59M revenue; segment losses (Corporate/Biosciences $(5.91)M; AGA $(1.74)M).
• Governance risks: CEO is also CFO; significant related‑party fees and bonuses; concentrated voting via Series B Preferred.

Risks

• Going concern uncertainty due to continued losses, negative operating cash flows, and need for additional capital.
• Dilution and market pressure from equity line conversions at a discount and multiple reverse stock splits.
• Collateralized financing: pledged equity and assets of AGA and Pacific Sun under the Streeterville facility; default could forfeit subsidiaries.
• Nasdaq listing risk and history of multiple reverse splits to regain/maintain compliance.
• Biotech development risk: EL-22/EL-32 may face regulatory hurdles (e.g., preclinical bridge studies) and may never achieve FDA approval.
• Regulatory and certification dependencies at AGA (ITAR, AS9100) and potential loss of certifications impacting revenue.
• PMGC Capital could be deemed an investment company under the 1940 Act if investment securities exceed thresholds, triggering burdensome regulation.
• Significant related‑party transactions and dual CEO/CFO role present conflicts of interest and oversight limitations.
• Cybersecurity and supply chain/trade policy risks across manufacturing and packaging operations.
• Listing, liquidity and volatility risks from limited public float and concentrated preferred voting power.

Future Outlook

Management plans to advance EL-22 toward a U.S. IND filing in 2026 (following a pre-IND meeting request submitted in February 2025), expand capacity and customer acquisition at Pacific Sun and AGA, pursue additional cash-generative acquisitions, and deploy capital through PMGC Capital to improve liquidity and returns.

Management Comments

• Strategy focuses on acquiring and scaling valuable assets across biotech, advanced manufacturing, and specialty packaging while allocating capital via PMGC Capital to drive returns.
• Northstrive Biosciences aspires to complete an IND submission in 2026 for EL-22, targeting muscle preservation in GLP-1-treated obesity patients.
• Pacific Sun aims to broaden its customer base in cloud/AI infrastructure and to expand next-generation component packaging offerings; AGA targets business development in aerospace/defense and capacity investments.

Industry Context

StockSavvy.ai notes PMGC is positioning EL-22 in the fast-growing GLP-1 obesity ecosystem where leaders like Novo Nordisk and Eli Lilly dominate, and several players (Biohaven, Scholar Rock, Veru) pursue muscle-preservation combinations. Pacific Sun’s packaging taps into data center and AI hardware growth, while AGA benefits from U.S. reshoring and defense supply-chain localization—tailwinds that could support revenue scaling if execution and capital are available.

Comparison to Industry Standards

• Biotech stage: As a pre-IND asset, EL-22 sits earlier than peers with active U.S. clinical programs (e.g., Biohaven’s taldefgrobep, Scholar Rock’s apitegromab); regulatory bridging and clinical validation remain ahead before competitive parity.
• Packaging margins: Pacific Sun’s normalized gross margin (~49%) compares favorably to specialty component packaging peers often in the ~25–40% range, suggesting room to leverage scale if volume grows.
• Precision machining: AGA’s current losses contrast with established aerospace/defense machine shops (10–20% EBITDA margins at scale); certification (ITAR/AS9100) is in place, but utilization and business development must improve to reach industry benchmarks.
• Capital structure: Reliance on discounted convertible/pre-paid equity facilities compares unfavorably to peers with traditional bank lines or non-dilutive government/defense contracts; collateral pledges are atypically risky for operating subsidiaries.

Corporate Governance

Legal Proceedings

• No active legal proceedings pending or threatened as of the filing date; routine legal risks acknowledged.

Related Party Transactions

• Consulting and milestone fees to GB Capital Ltd. (entity controlled by CEO/CFO): $697,800 in 2025; secondment reimbursements $159,996.
• Consulting and milestone fees to Northstrive Companies Inc. (entity controlled by Chairman): $764,600 in 2025; secondment reimbursements $382,707.
• Issued 6,372,874 shares of Series B Preferred Stock as sign-on/bonus to GB Capital Ltd. (3,036,437) and Northstrive Companies Inc. (3,336,437) on March 26, 2025, concentrating voting control.
• Unsecured revolving LOC with NorthStrive Fund II LP (controlled by Chairman) for $200,000 in 2024, repaid.

Stakeholder Impact

• Shareholders face significant dilution and volatility from discounted convertible/pre-paid equity structures and multiple reverse splits.
• Creditors gain collateral protection over AGA and Pacific Sun under the ELOC, elevating asset forfeiture risk on default.
• Employees and customers may benefit from operational certifications (ITAR, AS9100) and initial revenue traction but bear execution and financing risks.
• Suppliers and partners exposed to liquidity and market risks tied to PMGC’s financing structure and capital availability.

Next Steps

• Advance EL-22 toward an IND submission in 2026 following the February 2025 pre-IND meeting request.
• Integrate and scale Pacific Sun and AGA to grow revenue and margins; pursue new OEM/data center/defense customers.
• Evaluate and execute additional cash-generative acquisitions and portfolio optimization via PMGC Capital.
• Manage liquidity through capital deployment and potential financings while seeking to reduce cash burn.

Key Dates

Recommendation

The combination of going-concern uncertainty, widening losses, highly dilutive financing with pledged operating subsidiaries, repeated reverse stock splits, and governance/related-party risks outweighs early revenue traction and pipeline potential. Capital structure and default collateral terms pose material downside risk to equity holders.

Keywords

PMGC Holdings, ELAB, Northstrive Biosciences, EL-22, GLP-1 combination, engineered probiotic, Pacific Sun Packaging, AGA Precision Systems, CNC machining, ITAR, AS9100, Equity line of credit, Streeterville Capital, reverse stock split, going concern, registered direct offering, ATM program, pre-IND, Indarg Engineering, biotech obesity